Tygh Capital Management’s Trinity Biotech TRIB Stock Holding History

Tygh Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,170	Closed	-$2.01M	–	99
2015 Q3	$2.01M	Sell	1,170 -373	-24%	-$900K	0.48%	75
2015 Q2	$4.18M	Buy	1,543 +107	+7%	+$278K	0.75%	69
2015 Q1	$4.15M	Buy	1,436 +765	+114%	+$2.12M	0.76%	68
2014 Q4	$1.76M	Buy	671 +167	+33%	+$432K	0.34%	89
2014 Q3	$1.38M	Sell	504 -409	-45%	-$1.33M	0.3%	94
2014 Q2	$3.15M	Buy	+913	New	+$3.25M	0.67%	76

Other funds holding TRIB

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Tygh Capital Management's TRIB Position: Q4 2015 in Review

Tygh Capital Management sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 1,170 shares — an estimated $2.01M sold.

Tygh Capital Management first reported a position in TRIB in Q2 2014 and held it in 6 quarters. The position peaked at $4.18M in Q2 2015. 81 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

Tygh Capital Management reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
Tygh Capital Management sold 1,170 Trinity Biotech shares in Q4 2015, an estimated $2.01M.
Tygh Capital Management first reported a position in Trinity Biotech in Q2 2014 and held it in 6 quarters.
Tygh Capital Management's Trinity Biotech position peaked at $4.18M in Q2 2015.
81 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Tygh Capital Management's 13F filing for Q4 2015, filed 2 Feb 2016.